Parkinson’s disease drug hunters think outside the α-synuclein box - drbenjohnson
Parkinson’s disease is the fastest growing neurological condition, with no disease-modifying treatments to offer patients. At the center of the disease are neurotoxic clumps of the α-synuclein protein, so it is no surprise that most drugs in pipeline target α-synuclein with either small molecules, antibodies, peptide vaccines or gene therapies.
Choosing α-synuclein as a target for potential disease-modifying drugs is grounded in almost two decades of scientific findings. The protein is present throughout the body and ubiquitously in neurons. But in PD, it is abundant and forms aggregates of misfolded proteins contained in Lewy bodies, which are the hallmark of the disease.
Despite the uncertainties and the setbacks, “α-synuclein remains a viable and important target,” says Greenamyre. Those pursuing α-synuclein include Roche, who has initiated a fresh phase 2 trial of prasinezumab with a primary endpoint of improved motor signs, despite the negative results from the PASADENA trial.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
How to grow (almost) anything: a hybrid distance learning model for global laboratory-based synthetic biology education - Nature BiotechnologyA pilot program for synthetic biology education via a scalable distributed network model of distance-based laboratory learning can be accessible globally across disciplines and backgrounds.
続きを読む »
WSJ News Exclusive | Amgen in Advanced Talks to Buy Horizon TherapeuticsAmgen is in advanced talks to buy drugmaker Horizon Therapeutics, people familiar with the matter say, in a deal likely to be valued at well over $20 billion
続きを読む »
Investor group launches campaign to help companies protect natureHere's the plan: Select 100 companies whose business burdens nature. Then, offer advice on how to lighten their impact and monitor their progress.
続きを読む »
Chicago police warn residents about recent kitchen robberiesChicago police are warning residents about a string of recent robberies in the Greater Grand Crossing area.
続きを読む »
Jay Leno on Electric Cars, Hydrogen Fuel, Space Travel—and His Recent AccidentThe comedian and car lover has been very happy with the EVs he has bought. He is less interested in leaving Earth, though.
続きを読む »
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial - Nature MedicinePresented at ASH21: In the phase 1 EXPLORER trial, avapritinib, a selective KIT inhibitor, was generally well tolerated and elicited durable clinical and molecular responses in patients with advanced systemic mastocytosis MPNsm ASH22
続きを読む »